Aripiprazole, sold under the brand names Abilify and Aristada among others, is an atypical antipsychotic.
| FactSnippet No. 626,612 |
18 Facts About Aripiprazole
3.
Aripiprazole is primarily used for the treatment of schizophrenia or bipolar disorder.
| FactSnippet No. 626,614 |
4.
Aripiprazole is effective for the treatment of acute manic episodes of bipolar disorder in adults, children, and adolescents.
| FactSnippet No. 626,615 |
5.
Aripiprazole is an effective add-on treatment for major depressive disorder; however, there is a greater rate of side effects such as weight gain and movement disorders.
| FactSnippet No. 626,616 |
6.
Aripiprazole is not currently approved for the treatment of OCD and is instead used off-label for this indication.
| FactSnippet No. 626,617 |
7.
Aripiprazole has been reported to provide some benefit in improving cognitive functioning in people with ADHD without other psychiatric comorbidities, though the results have been disputed.
| FactSnippet No. 626,618 |
8.
Aripiprazole was discovered in 1988 by scientists at the Japanese firm Otsuka Pharmaceutical.
| FactSnippet No. 626,619 |
9.
Aripiprazole is a partial agonist of the serotonin 5-HT1A receptor.
| FactSnippet No. 626,620 |
10.
Aripiprazole was frequently found to be a partial agonist, with an intrinsic activity that could be low, intermediate, or high.
| FactSnippet No. 626,621 |
11.
Aripiprazole has a favorable pharmacological profile in being a 5-HT2A antagonist and a 5-HT2C partial agonist.
| FactSnippet No. 626,622 |
12.
Aripiprazole is a phenylpiperazine and is chemically related to nefazodone, etoperidone, and trazodone.
| FactSnippet No. 626,623 |
13.
Aripiprazole was discovered by scientists at Otsuka Pharmaceutical and was called OPC-14597.
| FactSnippet No. 626,624 |
14.
Aripiprazole has been approved by the FDA for the treatment of both acute manic and mixed episodes, in people older than ten years.
| FactSnippet No. 626,625 |
15.
Aripiprazole has been described as the prototypical third-generation antipsychotic, as opposed to first-generation antipsychotics like haloperidol and second-generation antipsychotics like clozapine.
| FactSnippet No. 626,626 |
16.
Aripiprazole was under development for the treatment of attention-deficit hyperactivity disorder, but development for this indication was discontinued.
| FactSnippet No. 626,627 |
17.
Aripiprazole has been studied for the treatment of amphetamine dependence and other substance use disorders, but more research is needed to support aripiprazole for these potential uses.
| FactSnippet No. 626,628 |
18.
Aripiprazole is under development for the treatment of agitation and pervasive child development disorders.
| FactSnippet No. 626,629 |